Opus Genetics is trading 9.25% up now at $4.49, with no new company-specific announcement identified for August 26, 2026.
- Latest major updates were August 6 second-quarter results and August 3 completion of enrollment in the OPGx-LCA5 Phase 3 trial.
- Those updates are too dated to establish a fresh catalyst.
- The broader market is mixed, while biotechnology ETF momentum has not clearly confirmed this pre-market move.